Prevalence of hyperglycemia among adult patients admitted with Covid-19 at Queen Elizabeth Central Hospital

Simple item page
dc.contributor.authorMvula, Bertha
dc.date.accessioned2021-12-21T11:51:01Z
dc.date.available2021-12-21T11:51:01Z
dc.date.issued2021-09-15
dc.description.abstractCoronavirus disease 2019 (COVID-19) is a highly infectious disease that is caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). It was declared a pandemic by the World Health Organization (WHO) in March 2020. The clinical spectrum of COVID-19 is heterogeneous, ranging from mild flu-like symptoms to acute respiratory distress syndrome, multiple organ failure and death. Among the risk factors, evidence indicates that patients with diabetes mellitus (existing or new diagnosis) are at increased risk of severe disease or death due to COVID-19 than those without diabetes. There is a lack of data on the prevalence, clinical presentation and outcomes of patients with hyperglycaemia and COVID-19 in African countries. Findings from this study will inform clinical guidelines on management of hyperglycaemia in COVID-19 patients in Malawi. Broad objective To determine the prevalence of hyperglycaemia in adult COVID-19 patients admitted with at QECH from 1 July 2021 to 28 February2022. Specific objectives 1. To determine the prevalence of known pre-existing diabetes mellitus in COVID-19 patients. 2. To determine the prevalence of new onset hyperglycaemia/previously undiagnosed type 2 diabetes mellitus in COVID-19 patients. 3. To describe the clinical characteristics of COVID-19 patients with hyperglycaemia. 4. To describe the clinical outcomes of COVID-19 patients with hyperglycaemia Study design: This will be an observational, analytic prospective cohort study. Study place: Queen Elizabeth Central Hospital (QECH), in Blantyre. Study population: All adult patients (aged 18 years or older) diagnosed with COVID-19 via RTPCR on nasopharyngeal swab specimens and admitted to all medical wards and other designated COVID-19 wards at Queen Elizabeth Central Hospital Study duration: 1 July 2021 to 28 February 2022 Data management and analysis: All participant data will be collected and entered on an electronic ODK tablet questionnaire, synced to a secure server, cleaned and consolidated in a password protected database. Prevalence of hyperglycaemia will be computed as the proportion of participants with elevated blood glucose level (≥200mg/dL) at admission. Associated factors for hyperglycaemia will be described, including clinical outcomes, while controlling for important demographic and clinical characteristics, including treatments administered during admission. Expected results We expect to know the prevalence of hyperglycaemia in adult patients with COVID-19 and ascertain the clinical course of and outcome of the patients. Findings from this study will inform clinical guidelines on management of hyperglycaemia in COVID-19 in Malawi. Dissemination of results: The results of this study will be disseminated to QECH, College of Medicine and Ministry of Health. They will also be disseminated at local, regional and international meetings/conferences and will also be published in peer reviewed journals. In addition to a thesis being submitted in fulfilment of a Master of Medicine degree, a copy of the final report and any enduing publications will be submitted to COMREC and the College of Medicine Library.en_US
dc.identifier.urihttp://rscarchive.kuhes.ac.mw/handle/20.500.12988/713
dc.language.isoenen_US
dc.publisherKamuzu University of Health Sciencesen_US
dc.relation.ispartofseriesProtocol;P.03/21/3291
dc.subjectResearch Subject Categories::MEDICINEen_US
dc.titlePrevalence of hyperglycemia among adult patients admitted with Covid-19 at Queen Elizabeth Central Hospitalen_US
dc.typePlan or blueprinten_US
Files
Collections
Protocol